- In May 2024, Pfizer Inc. announced an expanded partnership with Tempus, a leader in AI and precision medicine, to integrate real-time AI-driven analytics into its oncology clinical trials. This collaboration aims to accelerate patient identification and optimize trial protocols, reinforcing Pfizer’s commitment to AI-enabled drug development and personalized medicine initiatives across the U.S.
- In April 2024, Insilico Medicine, a U.S.-based biotech company utilizing AI for drug discovery, revealed the initiation of a Phase I clinical trial for a novel AI-designed drug targeting idiopathic pulmonary fibrosis. This milestone marks one of the first AI-generated drug candidates to reach human trials, highlighting the growing maturity and potential of AI platforms in transforming early-stage discovery into viable therapies
- In February 2024, Atomwise Inc., headquartered in California, entered into a multi-target drug discovery collaboration with Sanofi. This partnership leverages Atomwise’s AI-based structure-based drug design capabilities to identify novel small molecule candidates. The agreement emphasizes the pharmaceutical industry’s increasing reliance on AI to address complex therapeutic targets more efficiently
- In January 2024, XtalPi Inc., a U.S.-China dual-headquartered AI drug discovery company, announced the launch of its North America Innovation Center in Boston, Massachusetts. The new center will focus on quantum physics-based molecular modeling and generative AI for novel drug design, further positioning Boston as a hub for biotech innovation and expanding XtalPi’s capabilities in AI-powered R&D
- In December 2023, Recursion Pharmaceuticals, a Salt Lake City-based clinical-stage biotechnology company, secured a partnership with NVIDIA to integrate high-performance computing and AI to accelerate the discovery of therapeutics across rare diseases. This collaboration reflects the convergence of AI, large-scale biology, and computational platforms to unlock faster and more scalable drug discovery pipelines
